Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Richmond, Va – Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please click here.

Recent News


Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential


KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury


Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst